NTLA-3001

N/A

Report date: 2025/07/30 10:29:13

Base Information

Drug NameNTLA-3001
Drug Alias NameNTLA-3001
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionAlpha-1-antiproteinase modulators
TargetsAlpha-1-antiproteinase
Therapy Area/IndicationsLung Diseasesalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntellia Therapeutics Inc
Inactive CompaniesN/A
Active Indicationsalpha 1-Antitrypsin Deficiency
Inactive IndicationsLung Diseases

Other Information

ATC CodeN/A
Related LinksN/A